mAbxience Research clinical trials
mAbxience Research is the lead sponsor of 3 current clinical trials in our Spain, Italy, Portugal, Turkey, Brazil, Poland, Japan, South Korea, Taiwan and EU (CTIS) registers. 1 is recruiting patients now. All registered phases are Phase 3. The drugs named most often in its trials are Carboplatin, Cisplatin and EU-sourced Keytruda. The most-studied condition is Advanced (Unresectable or Metastatic) Melanoma.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by mAbxience Research
2 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
NCT07221734 · ClinicalTrials.gov ↗ · Advanced (Unresectable or Metastatic) Melanoma
|
Phase 3 | Recruiting | 2025-12 | Spain, Italy, Portugal, Turkey, Brazil |
|
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369 · ClinicalTrials.gov ↗ · Non Squamous Non Small Cell Lung Cancer
|
Phase 3 | Active, closed | 2024-12 | Spain, Italy, Poland, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
mAbxience Research in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System with mAbxience Research as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
2025-521562-95-00 · CTIS ↗ · Musculoskeletal Diseases
Drug: Nivolumab |
Phase 3 | Ongoing | Italy, Spain, Slovakia + 4 more |
Drugs in mAbxience Research trials
6 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in mAbxience Research trials
2 conditionsBy trial register
A trial with sites in more than one country appears in each of those registers.
Questions about mAbxience Research trials
How many clinical trials does mAbxience Research sponsor?
mAbxience Research is the lead sponsor of 2 current trials on ClinicalTrials.gov in our Spain, Italy, Portugal, Turkey, Brazil, Poland, Japan, South Korea and Taiwan registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are mAbxience Research trials recruiting?
Yes. 1 of its 2 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is mAbxience Research testing?
Its current trials name 6 drugs and biologicals as interventions. The most frequent are Carboplatin (1), Cisplatin (1), EU-sourced Keytruda (1), Nivolumab (1) and Pemetrexed (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.